You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

pMMR

Showing 1 - 25 of 89
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tislelizumab, Bevacizumab, Oxaliplatin Trial in Beijing (Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine)

Recruiting
  • Tislelizumab
  • +7 more
  • Beijing, China
    Lin Yang
Jul 21, 2023

Colorectal Cancer Trial in Koege (Influenza vaccine, Pembrolizumab)

Not yet recruiting
  • Colorectal Cancer
  • Koege, Zealand, Denmark
    Center for Surgical Science, Department of Surgery, Zealand Univ
Jun 9, 2023

Colorectal Cancer Trial (Serplulimab + FOLFOXIRI, Radiation therapy)

Not yet recruiting
  • Colorectal Cancer
  • Serplulimab + FOLFOXIRI
  • Radiation therapy
  • (no location specified)
Oct 24, 2023

Locally Advanced Colorectal Carcinoma Trial in Beijing (Cadonilimab, FOLFOX regimen)

Recruiting
  • Locally Advanced Colorectal Carcinoma
  • Beijing, Beijing, China
    Cancer Hospital/ National Cancer Center, Chinese Academy of Medi
Nov 23, 2023

Rectal Cancer, MSS Trial in Beijing (Cadonilimab, Oxaliplatin, Capecitabine)

Recruiting
  • Rectal Cancer
  • MSS
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
Apr 13, 2023

Locally Advanced Rectal Cancer Trial in Beijing (capecitabine, tislelizumab, thymalfasin)

Not yet recruiting
  • Locally Advanced Rectal Cancer
  • Beijing, China
  • +1 more
Sep 21, 2023

Metastatic Colorectal Cancer, mCRC Trial in Guangzhou (Tislelizumab & Fruquintinib)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • mCRC
  • Tislelizumab & Fruquintinib
  • Guangzhou, Guangdong, China
  • +1 more
Jan 25, 2023

Locally Advanced Colorectal Cancer Trial (Capecitabine, Oxaliplatin, Bevacizumab)

Not yet recruiting
  • Locally Advanced Colorectal Cancer
  • (no location specified)
Oct 18, 2022

Unresectable Colon Cancer Peritoneal Metastases, PMMR/Ras/BRAF Wild-type Trial in Huzhou (Serplulimab Combined With FOLFIRI and

Recruiting
  • Unresectable Colon Cancer Peritoneal Metastases
  • PMMR/Ras/BRAF Wild-type
  • Serplulimab Combined With FOLFIRI and Bevacizumab
  • Huzhou, Zhejiang, China
    Changxing County People's Hospital
Feb 14, 2023

Colorectal Cancer Liver Metastases Trial (CapOx(Capecitabine+ Oxaliplatin), Bevacizumab, Nivolumab)

Not yet recruiting
  • Colorectal Cancer Liver Metastases
  • CapOx(Capecitabine+ Oxaliplatin)
  • +2 more
  • (no location specified)
Oct 18, 2022

Recurrent Endometrial Carcinoma, Unresectable Endometrial Carcinoma Trial in Miami (Lenvatinib, Pembrolizumab, Hypofractionated

Not yet recruiting
  • Recurrent Endometrial Carcinoma
  • Unresectable Endometrial Carcinoma
  • Miami, Florida
    University of Miami
Jan 10, 2023

Colorectal Cancer, Colon Cancer, BRAF V600E Trial (Binimetinib)

Not yet recruiting
  • Colorectal Cancer
  • +4 more
  • (no location specified)
Aug 18, 2022

Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer Trial in Houston (Tecentriq 1200 MG in 20 ML Injection +

Not yet recruiting
  • Stage I Colon Cancer
  • +2 more
  • Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2
  • +2 more
  • Houston, Texas
    Baylor College of Medicine
May 22, 2023

Locally Advanced Rectal Cancer Trial in Guangzhou (AK104, Capecitabine, Neoadjuvant Radiotherapy)

Not yet recruiting
  • Locally Advanced Rectal Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 5, 2023

Rectal Cancer Trial (Short-course radiotherapy combined with furoquintinib and PD-1 mAb)

Not yet recruiting
  • Rectal Cancer
  • Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody
  • (no location specified)
Aug 29, 2023

Metastatic Colorectal Cancer Trial in Køge (Irreversible electroporation, Calcium electroporation, Pembrolizumab)

Recruiting
  • Metastatic Colorectal Cancer
  • Irreversible electroporation
  • +2 more
  • Køge, Denmark
    Zealand University Hospital
Jan 27, 2023

Colorectal Cancer Trial in Harbin (AK119, AK112, Oxaliplatin)

Not yet recruiting
  • Colorectal Cancer
  • Harbin, China
    Cancer Hospital Affiliated to Harbin Medical University
May 5, 2023

pMMR, MSS, MSI-L Trial (Serplilumab, Capecitabine, Oxaliplatin)

Not yet recruiting
  • pMMR
  • +3 more
  • (no location specified)
Feb 19, 2023

Colorectal Adenocarcinoma, Mucinous Adenocarcinoma, Signet Ring Cell Adenocarcinoma Trial in Trondheim, Lørenskog, Oslo

Not yet recruiting
  • Colorectal Adenocarcinoma
  • +2 more
  • Trondheim, Trondelag, Norway
  • +2 more
Aug 15, 2022

Rectal Cancer Trial (Trifluridine/Tipiracil, intensity-modulated radiotherapy)

Not yet recruiting
  • Rectal Cancer
  • (no location specified)
Jul 27, 2023

Mismatch Repair-proficient, Colorectal Cancer Metastatic, Microsatellite Stable Trial in Hangzhou (Tislelizumab, Irinotecan,

Recruiting
  • Mismatch Repair-proficient
  • +2 more
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Dec 17, 2021

Metastatic Microsatellite-stable Colorectal Cancer Trial in China (Experimental drug, Control Rx)

Recruiting
  • Metastatic Microsatellite-stable Colorectal Cancer
  • Experimental drug
  • Control Rx
  • Hefei, Anhui, China
  • +11 more
Mar 13, 2023

MSS, pMMR, Metastatic Colorectal Adenocarcinoma Trial in Shenyang (TKI ± anti-PD-1 antibody)

Recruiting
  • MSS
  • +2 more
  • TKI ± anti-PD-1 antibody
  • Shenyang, Liaoning, China
    Cancer Hospital of China Medical University/Liaoning Cancer Hosp
Sep 28, 2021

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

Neoadjuvant Chemotherapy and Immunotherapy for HER2(-),pMMR

Recruiting
  • Gastric Cancer
  • SOX plus Paclitaxel(albumin-bound) followed by PD-1 antibody
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Sep 12, 2022